Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
89.65
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Thera
< Previous
1
2
3
4
5
Next >
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
June 28, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
June 01, 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 30, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 08, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
May 01, 2023
One World Trade Center to be lit up in green in observance of Mental Health Month
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
NASDAQ: AXSM Shareholder Notice: Investigation over Potential Wrongdoing at Axsome Therapeutics, Inc.
April 27, 2023
San Diego, CA -- (SBWIRE) -- 04/27/2023 -- Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of
April 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 14, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
April 13, 2023
Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Long Term Investor Alert: Lawsuit Against Directors Filed
February 17, 2023
San Diego, CA -- (SBWIRE) -- 02/17/2023 -- An investor in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) filed a lawsuit against certain directors of Axsome Therapeutics, Inc. over alleged breaches...
Via
SBWire
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
January 31, 2023
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
December 07, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
November 30, 2022
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
Via
MarketBeat
Exposures
Product Safety
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 09, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
October 27, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
October 21, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
October 20, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
October 10, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea
October 03, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME THERAPEUTICS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM
August 26, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.